Dr. Cachia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Worcester, MA 01655Phone+1 508-334-3550Fax+1 774-442-9130
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 2013 - 2015
- UMass Chan Medical SchoolFellowship, Clinical Neurophysiology, 2012 - 2013
- UMass Chan Medical SchoolResidency, Neurology, 2009 - 2012
- UMass Chan Medical SchoolInternship, Internal Medicine, 2008 - 2009
- University of Malta School of MedicineClass of 2001
Certifications & Licensure
- MA State Medical License 2011 - 2025
- SC State Medical License 2015 - 2023
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Alpha Omega Alpha Medical Honor Society 2012
- Clinical Scholars Award MUSC (Medical University of South Carolina) Cancer Center, 2017
- Faculty Excellence Educator of the Block Award (2) MUSC (Medical University of South Carolina), 2016
- Join now to see all
Publications & Presentations
PubMed
- 29 citationsAlliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With SomaticMutations.Priscilla K Brastianos, Erin L Twohy, Elizabeth R Gerstner, Timothy J Kaufmann, A John Iafrate
Journal of Clinical Oncology. 2023-01-20 - 15 citationsEvaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigationsArabinda Das, Mohammed Alshareef, J. L. Martinez Santos, Guilherme B. F. Porto, Daniel G. McDonald
Clinical & Translational Oncology. 2020-04-06 - 44 citationsLeptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institutionJacob Mandel, Shlomit Yust-Katz, David Cachia, Jimin Wu, Diane Liu
Journal of Neuro-Oncology. 2014-08-29
Journal Articles
- Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastomaMandel JJ, Yust-Katz S, Patel A, Cachia D, Liu D, Park M, Yuan Y, Kent K, de Groot JF, Neuro Oncol, 1/10/2018
- Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patientsCachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, Colen R, DeGroot JF, J Neurooncol, 1/1/2017
- Dorsal Column Myelopathy after Intrathecal Chemotherapy for LeukemiaPinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Oh..., Am J Hematol, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Overcoming Radiation Resistance in Meningioma: The Emerging Role of CDK4/6 Inhibitor.Cachia D, Society of Neuro-Oncology Meeting, New Orleans, LA, 1/1/2018
- C18-Ceramide Analogue Drug Overcomes Resistance to Temozolomide in Gliobastoma.Cachia D, Society of Neuro-Oncology Meeting, New Orleans, LA, 1/1/2018
- Galectin-1 upregulates CXCR4 in glioblastoma through upregulation of CXCR4 via NF-KappaB activation.Cachia D, American Association for Cancer Research, 1/1/2018
- Join now to see all
Lectures
- Treatment of Diffuse Gliomas in Adults: What's New?1/1/2018
- Anti-Tumor Activity of CDK 4/6 Inhibitor Palbociclib in Rb+ Meningioma: Pre-clinical Assessment.1/1/2016
- RIP3 is a Critical Regulator of Radiation Induced Programmed Necrosis and Inflammation in a Preclinical Model of Glioblastoma.1/1/2016
- Join now to see all
Press Mentions
- MUSC Studying How COVID-19 Impacts Those with CancerFebruary 25th, 2021
- Study Seeks to Better Understand How COVID-19 and Cancer IntersectFebruary 8th, 2021
- MUSC Using Virus to Fight Brain CancerOctober 11th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: